Seattle Genetics Forms ADC Pact with Bayer - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Seattle Genetics Forms ADC Pact with Bayer
Seattle Genetics could potentially receive approximately $500 million in fees, milestones and royalties.

Seattle Genetics announced that it has entered into an antibody-drug conjugate (ADC) collaboration with Bayer. Under the terms of the agreement, Bayer will pay upfront and option exercise fees of up to $20 million for worldwide rights to use Seattle Genetics’ auristatin-based ADC technology with antibodies to several cancer targets.

Seattle Genetics is also eligible to receive up to approximately $500 million in milestone payments and royalties on sales of any products resulting from the collaboration. Bayer will conduct research and development and be responsible for manufacturing and commercialization of all products under this collaboration.

ADCs are monoclonal antibodies that selectively deliver cytotoxic agents to targeted cancer cells. Seattle Genetics has developed proprietary technology to attach synthetic cytotoxic agents to the antibody using stable linker systems that are designed to be stable in the bloodstream. The targeted delivery spares healthy cells from the many toxic effects of traditional chemotherapy while enhancing antitumor activity.

Seattle Genetics has also extended its collaboration pact with Agensys, an affiliate of Astellas, and announced co-development of an additional ADC under the companies’ existing ADC agreement. The ADC, called ASG-15ME, targets the tumor antigen SLITRK6, known to be expressed on bladder and lung cancer. Agensys has submitted an investigational new drug (IND) application to FDA for initiation of a Phase I trial of ASG-15ME.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here